Aprea Therapeutics Inc (APRE) - News Archive

Aprea Therapeutics Advances in Oncology: ATRN-119 Dual Dosing Approach and Promising Next-Gen Inhibitors Aprea Therapeutics, a prominent player in the field of oncology, has strategically advanced its clinical and resea...

In the ever-competitive healthcare sector, Aprea Therapeutics Inc finds itself at a pivotal moment. Recently, the company recorded a cumulative net loss of $13 million over the twelve months ending in the second quarter...

Aprea Therapeutics Expands Expertise with Appointment of Philippe Pultar, MD, to Lead WEE1 Clinical Development Amid New Trial InitiativesAprea Therapeutics Inc. a clinical-stage biopharmaceutical company specializing i...

In a recent development, Aprea Therapeutics, a clinical-stage biopharmaceutical company dedicated to precision oncology through synthetic lethality, announced the initiation of the ACESOT-1051 Phase 1 trial. The trial a...

The Potentials Unveiled - WEE1 Inhibitor APR-1051 & ATR Inhibitor ATRN-119Aprea Therapeutics, a leader in developing cutting-edge cancer therapeutics, unveiled intriguing results relating to their two investigational co...

(Article Body)In a recent announcement made by Aprea Therapeutics Inc, the biotechnology company shared news of a private placement financing round that could potentially yield up to $34.0 million. The financing, led by...

In the field of oncology, precision medicine has revolutionized the way cancer is diagnosed and treated. One promising area of research is synthetic lethality, which focuses on exploiting weaknesses in cancer cells that...